ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
Audio recording of the Investor Call on unaudited financial results for the quarter ended on June 30, 202303-08-2023
03-08-2023
Q1FY24 Quarterly Result Announced for Zydus Wellness Ltd.
Packaged foods company Zydus Wellness announced Q1FY24 results: Company reported net sales of Rs 699 crore for Q1FY24. Company reported a total income from operations of Rs 702 crore and a net profit of Rs 110 crore for Q1FY24. Five of its brands, Glucon-D, Sugar-Free, EverYuth Scrub, Peel Off Face Mask, and Nycil maintained their leadership positions in their respective categories as on June 2023. Glucon-D has with a market share of 59.9 per cent maintained its number one position. Sugar-Free continues to maintain its leadership with a market share of 96.2 per cent. Nycil has maintained its dominant position by further increasing its market share by 117 basis points over Q1FY23, which now stood at 35.5 per cent in the Prickly heat powder category. Complan has registered progressive improvement in volume market share during Q1FY24. During Q1FY24, the Company’s subsidiary in Bangladesh became operational thereby strengthening its international presence. Result PDF03-08-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Press Release / Media Release
Copy of press release dated August 3, 2023 proposed to be published in the newspapers in the matter of unaudited financial results for the quarter ended on June 30, 2023.03-08-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Investor Presentation
Investor presentation on the unaudited financial results for the quarter ended on June 30, 2023.03-08-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Board Meeting Outcome for Unaudited Financial Results For The Quarter Ended On June 30, 2023
Unaudited financial results for the quarter ended on June 30, 202303-08-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Unaudited Financial Results For The Quarter Ended On June 30, 2023
Unaudited financial results for the quarter ended June 30, 202303-08-2023
Zydus Lifesciences gains 5% on USFDA nod for cancer drug
The plerixafor injection, used by patients with certain types of cancer to prepare them for a stem cell transplant, will be manufactured at the group's facility in Ahmedabad27-07-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
Schedule of Analyst / Institutional Investors' call25-07-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Board Meeting Intimation for Approval Of Unaudited Financial Results For The Quarter Ended On June 30, 2023
ZYDUS WELLNESS LTD.-has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 03/08/2023 ,inter alia, to consider and approve unaudited financial results for the quarter ended on June 30, 202324-07-2023
ZYDUS WELLNESS LTD.-$ - 531335 - Compliances-Reg. 39 (3) - Details of Loss of Certificate / Duplicate Certificate
Intimation of loss of share certificate / issue of duplicate share certificate under Regulation 39(3) of the SEBI (LODR) Regulations, 201515-07-2023